Results From A Study Testing Methylphenidate For Cancer-Related Fatigue Indicate That It Is Certainly Not A Panacea But May Be Effective For Some Groups Of Patients

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.